All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Phase I/II trial of SAR443579 in patients with R/R AML, B-ALL, or HR-MDS
Featured
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing the preliminary safety and efficacy results from the phase I/II trial (NCT05086315) investigating SAR443579 (SAR’579), a trifunctional anti-CD123 NKp46×CD16 natural killer cell engager, in patients with relapsed/refractory acute myeloid leukemia.1,2
Preliminary results from this trial were presented by Stein1,2 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2023 Hybrid Congress. No dose-limiting toxicities were identified. Based on the results of this analysis, the study protocol was amended to assess a higher dose of SAR’579.1,2
- Stein AS. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. Oral abstract #7005. 2023 American Society of Clinical Oncology Annual Meeting; Jun 2, 2023; Chicago, US.
- Stein AS. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia. Poster #P494. European Hematology Association 2023 Hybrid Congress; Jun 9, 2023; Frankfurt, DE.
Your opinion matters
28 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox